Kazia Therapeutics Agreement and Intellectual Property

January 22nd, 2018 by Blog Author

In response to shareholder enquiry, this is a clarifying note about the agreement recently entered into between NOX and KZA. The agreement represents a commercial decision reached by both parties that provides NOX with the certainty it needs as it prepares to enter a Phase 2/Phase 3 clinical program for its lead drug candidate, NOX66. […]

Read More